Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...

Pfizer (NYSE:PFE) experienced a 2.98% price move over the past month, coinciding with new strategic collaborations. Notably, ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.